FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica said it plans to launch the trial later in 2026
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The company announced positive topline data from the Phase II ZUPREME-1 trial
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
Subscribe To Our Newsletter & Stay Updated